Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.
about
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the fieldPreclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationIntegrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinomaInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationSrc activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinasesFGF receptors: cancer biology and therapeuticsA Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.Targeted therapies for adrenocortical carcinoma: IGF and beyond.Novel targeted therapies for eosinophil-associated diseases and allergyTyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells.The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic LeukemiaPonatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeDovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalitiesAxl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Chinese herb related molecules of cancer-cell-apoptosis: a minireview of progress between Kanglaite injection and related genesTyrosine kinase gene rearrangements in epithelial malignancies.Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.Targeting mutant fibroblast growth factor receptors in cancer.Fibroblast growth factors and their receptors in cancer.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Acute myeloid leukemia associated with FGFR1 abnormalities.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusionA FGFR1 inhibitor patent review: progress since 2010.Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.
P2860
Q27003331-ED9472AE-373C-49B7-8F2C-8F419CFEC98EQ27322795-89FABB8E-FEB4-4AAD-815D-816598409856Q27852856-BF81A6A4-1CDA-4452-9554-91EBF678D5E0Q28079309-20964623-5448-47D7-B4C1-5B92E3866574Q28248761-1DA62B55-28D1-4AD9-9225-46290F968B0FQ28291186-6B3EFC38-1E29-4DDA-A5D6-938A210507A0Q30252721-1482AE40-6882-4F17-9332-B64C69BE68E2Q34101433-B7F5D8D5-001B-4579-8B49-C74B19C58EE6Q34444620-872611C4-6DED-40BC-AAB4-562733AE7EE8Q34495630-70861F07-8873-4675-B353-E175227F0762Q34542012-02FCE018-9C01-4197-9912-D0A3AD8A61FFQ35018563-570593F7-B649-48DA-80DE-0D1A01E34446Q35585501-2CF715DA-44B4-4E2B-8BF3-FA5C38C9AF15Q35895967-FE67523A-B402-4D62-A87B-4638FDE2845AQ36307383-883F59FC-903E-4202-9860-AC331EFFA097Q36498390-D1C035D3-7BF0-4DE1-ABF0-51DDDA7A10A0Q36555872-DFDD603D-C919-4217-8CFE-491A61E88CE5Q36776253-4E2E5B7C-DCAB-4B53-A9C1-BA260452B4D9Q36932683-8828790F-6D1F-42D5-BC3C-858776652B6CQ37061044-9BC239FF-817C-4BBF-B4AC-9EC47F75D60FQ37248816-7341549D-629A-496E-9D18-6058A6C57BB1Q37515966-D830EFAB-4995-43A5-827D-F348792F5657Q37598944-5504D01C-63A2-4B19-A6E6-9806594B4339Q37717519-BE628F57-4D65-433A-AB59-8D8A7BAB2E72Q37724934-91B8B50A-F8C0-4D24-BA97-8ECD8C788D00Q37849013-4494ECDF-FC16-4A6C-940F-FDEA37450C51Q37895306-907D6EEB-0F11-40D1-9920-BA69EF1F9F8BQ37919976-6CFB0E2A-17D5-4B86-A457-D3DFC71D09A3Q38100975-B0F7A181-0F8D-4C2F-8D5C-0194390FA3F1Q38131481-1583A052-E793-4788-83BF-396604238F02Q38212165-E55534B6-0650-4C84-BCED-C27533F8CEE1Q38718712-A23104D9-B857-4320-837B-930E0E0DC414Q38782612-6A14C171-FB61-4288-80D8-CCD8FD05CD57Q38833773-3E3ACF67-8AFA-4F06-B099-03F7A784D5A9Q39120148-F78B6E60-C26C-4E5A-B1B9-252A53BE4E2BQ39300448-881FBEDA-3440-4C39-825E-3B633CA1F5B1Q40214485-43282062-BC56-4112-9A88-517ABB3DA82FQ40974422-AE99C49E-1240-41D6-A72B-7E36F611E8D9Q42793025-AFC06641-4964-4292-ADC9-24D7009F1132Q44096802-6A61B433-E36F-46C6-8F52-910E86545FBC
P2860
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activity of TKI258 against pri ...... 1 myeloproliferative syndrome.
@en
type
label
Activity of TKI258 against pri ...... 1 myeloproliferative syndrome.
@en
prefLabel
Activity of TKI258 against pri ...... 1 myeloproliferative syndrome.
@en
P1433
P1476
Activity of TKI258 against pri ...... 11 myeloproliferative syndrome
@en
P2093
Andrew Chase
Francis H Grand
P304
P356
10.1182/BLOOD-2007-02-074286
P407
P577
2007-08-13T00:00:00Z